Diabetes mellitus (DM) has become a serious public health problem. There are many types of hypoglycemic drugs and various treatment options available to treat DM, especially with the approval and marketing of new hypoglycemic drugs. Improper use of hypoglycemic drugs can cause drug-related problems (DRP), which affects the effectiveness of treatment. As a chronic disease, DM requires long-term medication treatment. Poor medication adherence can lead to disease progression, disability, and death.
Pharmaceutical care programs are crucial for the management of DM. It is necessary to comprehensively evaluate the economic, clinical, and humanistic outcomes of pharmaceutical care programs in the care of diabetes. It is also essential to assess the effectiveness, safety, and economics of diabetic drugs and treatment regimens to provide a basis for clinical and management decisions.
This Research Topic aims to collect papers describing innovative pharmaceutical care programs and the outcome evaluation of pharmaceutical care programs in diabetes care. It also seeks to include articles that evaluate the effectiveness, safety (pharmacovigilance), and economics (pharmacoeconomics) of drug therapies.
We welcome Original Research articles, Reviews (especially Systematic Reviews and Meta-analyses), and Case Reports on the subtopics of interest, which include but are not limited to:
• Economic, clinical, or humanistic outcome evaluation of practice innovation
• Pharmacoeconomic evaluation of diabetes drugs and treatment
• Pharmacovigilance studies on the safety of diabetes drugs
• Studies evaluating the effectiveness or efficacy of diabetes drugs and treatment
Diabetes mellitus (DM) has become a serious public health problem. There are many types of hypoglycemic drugs and various treatment options available to treat DM, especially with the approval and marketing of new hypoglycemic drugs. Improper use of hypoglycemic drugs can cause drug-related problems (DRP), which affects the effectiveness of treatment. As a chronic disease, DM requires long-term medication treatment. Poor medication adherence can lead to disease progression, disability, and death.
Pharmaceutical care programs are crucial for the management of DM. It is necessary to comprehensively evaluate the economic, clinical, and humanistic outcomes of pharmaceutical care programs in the care of diabetes. It is also essential to assess the effectiveness, safety, and economics of diabetic drugs and treatment regimens to provide a basis for clinical and management decisions.
This Research Topic aims to collect papers describing innovative pharmaceutical care programs and the outcome evaluation of pharmaceutical care programs in diabetes care. It also seeks to include articles that evaluate the effectiveness, safety (pharmacovigilance), and economics (pharmacoeconomics) of drug therapies.
We welcome Original Research articles, Reviews (especially Systematic Reviews and Meta-analyses), and Case Reports on the subtopics of interest, which include but are not limited to:
• Economic, clinical, or humanistic outcome evaluation of practice innovation
• Pharmacoeconomic evaluation of diabetes drugs and treatment
• Pharmacovigilance studies on the safety of diabetes drugs
• Studies evaluating the effectiveness or efficacy of diabetes drugs and treatment
